The Zacks: Brokerages Expect OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) Will Announce Earnings of -$0.47 Per Share

The Zacks: Brokerages Expect OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) Will Announce Earnings of -$0.47 Per Share

On average, analysts expect that OncoMed Pharmaceuticals will report full year earnings of ($1.83) per share for the current financial year, with EPS estimates ranging from ($2.31) to ($1.57). For the next fiscal year, analysts expect that the business will post earnings of ($1.32) per share, with EPS estimates ranging from ($1.92) to ($0.24). Zacks’ earnings per share calculations are a mean average based on a survey of research firms that cover OncoMed Pharmaceuticals.

Brokerages expect OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) to announce earnings of ($0.47) per share for the current fiscal quarter, according to Zacks. Three analysts have made estimates for OncoMed Pharmaceuticals’ earnings, with estimates ranging from ($0.65) to ($0.37). OncoMed Pharmaceuticals reported earnings per share of ($0.91) in the same quarter last year, which would indicate a positive year over year growth rate of 48.4%. The business is expected to report its next quarterly earnings results on Tuesday, August 8th.

OncoMed Pharmaceuticals (NASDAQ:OMED) last posted its earnings results on Monday, May 8th. The biopharmaceutical company reported ($0.61) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.62) by $0.01. The business had revenue of $6.20 million for the quarter, compared to the consensus estimate of $5.85 million. The business’s revenue was down 2.4% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.90) earnings per share.

A number of equities analysts have recently issued reports on OMED shares. Zacks Investment Research raised shares of OncoMed Pharmaceuticals from a “hold” rating to a “buy” rating and set a $10.00 price objective on the stock in a research report on Thursday, March 23rd. BMO Capital Markets reissued a “buy” rating and set a $18.00 price objective on shares of OncoMed Pharmaceuticals in a research report on Tuesday, March 14th. HC Wainwright set a $20.00 price objective on shares of OncoMed Pharmaceuticals and gave the stock a “buy” rating in a research report on Saturday, March 11th. Jefferies Group LLC reissued a “buy” rating and set a $10.00 price objective (down previously from $15.00) on shares of OncoMed Pharmaceuticals in a research report on Tuesday, April 11th. Finally, SunTrust Banks, Inc. cut shares of OncoMed Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Monday, April 17th. One analyst has rated the stock with a sell rating, seven have given a hold rating and two have issued a buy rating to the company. OncoMed Pharmaceuticals presently has an average rating of “Hold” and an average target price of $8.63.

OncoMed Pharmaceuticals (NASDAQ:OMED) traded down 1.16% on Monday, reaching $3.42. The company’s stock had a trading volume of 113,514 shares. OncoMed Pharmaceuticals has a 12 month low of $3.14 and a 12 month high of $13.27. The stock’s 50 day moving average price is $3.57 and its 200 day moving average price is $6.60. The company’s market cap is $128.67 million.

In other OncoMed Pharmaceuticals news, Director Perry A. Karsen purchased 10,000 shares of the company’s stock in a transaction that occurred on Monday, June 5th. The shares were acquired at an average price of $3.46 per share, with a total value of $34,600.00. Following the transaction, the director now owns 10,000 shares in the company, valued at $34,600. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Jonathan D. Root sold 7,487 shares of the firm’s stock in a transaction dated Friday, May 19th. The shares were sold at an average price of $3.70, for a total transaction of $27,701.90. Following the completion of the transaction, the director now directly owns 121,020 shares in the company, valued at approximately $447,774. The disclosure for this sale can be found here. Insiders have bought a total of 88,121 shares of company stock worth $304,289 in the last three months. Insiders own 32.80% of the company’s stock.

Institutional investors have recently made changes to their positions in the stock. Metropolitan Life Insurance Co. NY acquired a new position in shares of OncoMed Pharmaceuticals during the first quarter valued at $160,000. Highbridge Capital Management LLC boosted its position in shares of OncoMed Pharmaceuticals by 34.6% in the first quarter. Highbridge Capital Management LLC now owns 49,372 shares of the biopharmaceutical company’s stock valued at $455,000 after buying an additional 12,698 shares during the last quarter. Bank of America Corp DE boosted its position in shares of OncoMed Pharmaceuticals by 11.3% in the first quarter. Bank of America Corp DE now owns 156,596 shares of the biopharmaceutical company’s stock valued at $1,442,000 after buying an additional 15,850 shares during the last quarter. Schwab Charles Investment Management Inc. boosted its position in shares of OncoMed Pharmaceuticals by 6.0% in the first quarter. Schwab Charles Investment Management Inc. now owns 81,999 shares of the biopharmaceutical company’s stock valued at $756,000 after buying an additional 4,617 shares during the last quarter. Finally, KCG Holdings Inc. acquired a new position in shares of OncoMed Pharmaceuticals during the first quarter valued at $103,000. 44.55% of the stock is currently owned by institutional investors and hedge funds.

OncoMed Pharmaceuticals Company Profile

OncoMed Pharmaceuticals, Inc (OncoMed) is a clinical-stage biopharmaceutical company. The Company focuses on discovering and developing therapeutics that address the fundamental biology driving cancer’s growth, resistance, recurrence and metastasis. The Company’s therapeutic candidates and preclinical programs include Demcizumab (Anti-DLL4, OMP-21M18), Tarextumab (Anti-Notch2/3, OMP-59R5), Vantictumab (anti-Fzd7, OMP-18R5), Ipafricept (Fzd8-Fc, OMP-54F28), Brontictuzumab (Anti-Notch1, OMP-52M51), Navicixizumab (Anti-DLL4/VEGF Bispecific, OMP-305B83), Anti-RSPO3 (OMP-131R10), Anti-TIGIT (OMP-313M32) and GITRL-Fc trimer (OMP-336B11).

Get a free copy of the Zacks research report on OncoMed Pharmaceuticals (OMED)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Related posts

Leave a Comment